Press Releases

15

Feb, 2022

European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients

Tags: ,

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                   “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA’s recombinant Covid-19 vaccine in children (including adolescents) and immunocompromised people. The trials will last 2.5 years. […]

READ MORE

14

Jun, 2021

A conceptual approach to the rationale for SARS-CoV-2 vaccine allocation prioritisation

Tags: ,

Authors: MK. Vasconcelos, C. Marazia, M. Koniordou, H. Fangerau, I. Drexler & AAA. Awuah Published in: Taylor and Francis Online   ABSTRACT Currently vaccines protecting from COVID-19 are a scarce resource. Prioritising vaccination for certain groups of society is placed in a context of uncertainty due to changing evidence on the available vaccines and changing infection dynamics. To meet accepted ethical standards of procedural justice and individual autonomy, vaccine allocation strategies need to state reasons for prioritisation explicitly while at the same time communicating the expected risks and benefits of vaccination at […]

READ MORE

19

Mar, 2021

Vaccinating Children against Covid-19 — The Lessons of Measles

Tags: , ,

Authors: Perri Klass, M.D. and Adam J. Ratner, M.D., M.P.H. Published in: The New England Journal of Medicine   Introduction: Imagine a highly contagious virus circulating in the community. Many infected children have fever and some general misery but recover without incident. Rarely, devastating complications occur, leading to hospitalization, severe illness, and occasional deaths. Susceptible adults fare worse, with higher rates of poor outcomes. Would you want your child vaccinated against this disease? You guessed we were talking about measles, right? As the first SARS-CoV-2 vaccines are rolled out to […]

READ MORE

23

Feb, 2021

What does 95% COVID-19 vaccine efficacy really mean?

Tags: , ,

Author: Piero Olliaro Published in: The Lancet Introduction: It is imperative to dispel any ambiguity about how vaccine efficacy shown in trials translates into protecting individuals and populations. The mRNA-based Pfizer1,2 and Moderna3 vaccines were shown to have 94–95% efficacy in preventing symptomatic COVID-19, calculated as 100 × (1 minus the attack rate with vaccine divided by the attack rate with placebo). It means that in a population such as the one enrolled in the trials, with a cumulated COVID-19 attack rate over a period of 3 months of about […]

READ MORE

26

Jan, 2021

Prof. Timo Vesikari talks to us about COVID-19 vaccines and children

Tags: , ,

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children. Read the interview here

READ MORE
NEWSLETTER

We would like to update you on our recent activities